Strategy development and priority setting
Our principal goal is to devise a strategy for clinical studies in SpA which will result in well designed clinical trials which Arthritis Research UK will wish to fund and which can be delivered with the help of the infrastructure put in place by the UK government in the form of clinical research networks.
As part of Arthritis Research UK's new strategy for funding clinical trials, Clinical Studies Groups (CSGs) have been set up in seven major clinical areas, one of which is spondyloarthritis (SpA) – i.e. ankylosing spondylitis, psoriatic arthritis, the arthritis of inflammatory bowel disease, reactive arthritis and undifferentiated spondyloarthritis.
No decisions on whether other forms of arthritis (e.g. SAPHO) might be within our remit have been made and the CSG is open to suggestions on this.
- Core values for the CSG
- Transparency and openness
- Goal–oriented – we must facilitate the development, in a useful time frame, of robust clinical trial proposals which command wide support in the SpA community and will be very fundable by Arthritis Research UK
For more information please read the Spondyloarthopathies CSG strategy (PDF 104 KB)